A venture capital firm backed by a major global financial services group actively invests across multiple sectors, including life sciences. The firm typically invests USD 1–2 million per round, though it is capable of larger allocations depending on the opportunity. While globally active, the firm focuses on opportunities with strong relevance to specific market needs in Asia.
In the life sciences space, the firm is currently targeting therapeutic and medtech products that address major unmet medical needs in its home market. It favors companies with a clear strategy to collaborate with regional pharmaceutical partners, whether through licensing, co-development, or strategic equity participation. The firm considers a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated drugs. It primarily seeks products in Phase I clinical trials but may also invest in assets within one year of entering the clinic. Indications of strong interest include oncology and orphan diseases.
The firm only co-invests in opportunities outside of its home country and strongly prefers that a reputable institutional lead or established syndicate be in place before participating. As such, it tends to evaluate international deals with a co-investment mindset alongside other institutional investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment